@DrAttai @AnaBaracCardio https://t.co/irKZ20mnJw Safety of HER2 therapies in patients with LVEF 40-49%. 14 patients enrolled were treated with trastuzumab/pertuzumab. @AnaBaracCardio @claudine_isaacs @SandraSwainMD
RT @OncoCard_Ganken: @ACCinTouch #CardioOnc It's reasonable to continue or initiate HER2-targeted Tx in pts w/ mild LV dysfunction w/o a…
@ACCinTouch #CardioOnc It's reasonable to continue or initiate HER2-targeted Tx in pts w/ mild LV dysfunction w/o a symptom of HF with close cardiac follow-up. -SAFE-HEaRt trial https://t.co/gTn51UYxmx @AnaBaracCardio Agree🤞😮 ハーセプチンは案外なんとかなります https:
RT @OncoCard_Ganken: ■Memo Prospective evaluation of the cardiac safety of HER2-targeted Tx in pts with HER2-positive breast cancer and com…
■Memo Prospective evaluation of the cardiac safety of HER2-targeted Tx in pts with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study https://t.co/QWR3i6oiOA 90% were able to complete their planned Tx w/ TZM despite an LVEF o
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. https://t.co/qzzH1FSUl9
RT @datsunian: Congrats Ana @AnaBaracCardio on this long awaited #cardioonc study!! This is a hopeful step into an future where lifesaving…
Congrats Ana @AnaBaracCardio on this long awaited #cardioonc study!! This is a hopeful step into an future where lifesaving anti-HER2 tx won't be turned away from pts with LV dysfunction, with close fu, care, & collaboration with our cancer colleagues.